Securities: securities fraud action:
limitations period: on November 6, 2003, respondent investors filed a
securities fraud action under §10(b) of the Securities Exchange Act of 1934,
alleging that petitioner Merck & Co. knowingly misrepresented the heart attack
risks associated with its drug Vioxx. A securities fraud complaint is timely if
filed no more than “2 years after the discovery of the facts constituting the
violation” or 5 years after the violation. 28 U. S.
C. §1658(b); the limitations period in §1658(b)(1) begins to run once the
plaintiff actually discovered or a reasonably diligent plaintiff would have
“discovered the facts constituting the violation”—whichever comes first. In the
statute of limitations context, “discovery” is often used as a term of art in
connection with the “discovery rule,” a doctrine that delays accrual of a cause
of action until the plaintiff has “discovered” it; facts showing
scienter are among those that “constitute the violation.” Scienter is assuredly
a “fact.” In a §10(b) action, it refers to “a mental state embracing intent to
deceive, manipulate, or defraud,” Ernst & Ernst v. Hochfelder,
425 U. S. 185, 194, n. 12, and “constitutes” an important and necessary element
of a §10(b) “violation.” See Tellabs, Inc. v. Makor Issues &
Rights, Ltd., 551 U. S. 308, 319; it would frustrate the very purpose of
the discovery rule codified in §1658(b)(1) if the limitations period began to
run regardless of whether a plaintiff had “discovered” any facts suggesting
scienter (U.S.S.Ct., 27.04.10, Merck v. Reynolds, J. Breyer).
Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts
Tuesday, April 27, 2010
Merck v. Reynolds
Subscribe to:
Posts (Atom)